Free tool
FAERS Monitor: Ultravist 150
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020220 or its brand name (Ultravist 150, Iopromide). Reports on generic versions are filed under their own applications.
Reports
4,182
Serious
3,709
89% of reports
Hospitalization
1,357
Death reported
336
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea621
- urticaria545
- pruritus481
- erythema394
- anaphylactic shock389
- blood pressure decreased376
- nausea320
- vomiting293
- loss of consciousness255
- oxygen saturation decreased248
- dizziness230
- rash228
- contrast media allergy214
- hypotension193
- chest discomfort180
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 7 |
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 13 |
| 2009 | 29 |
| 2010 | 15 |
| 2011 | 17 |
| 2012 | 103 |
| 2013 | 194 |
| 2014 | 208 |
| 2015 | 231 |
| 2016 | 239 |
| 2017 | 203 |
| 2018 | 229 |
| 2019 | 198 |
| 2020 | 282 |
| 2021 | 176 |
| 2022 | 279 |
| 2023 | 413 |
| 2024 | 493 |
| 2025 | 456 |
| 2026 | 392 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,977 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| contrast media allergySignal | 214 | 665.3 | 578.8 | 124,804 |
| anaphylactic shockSignal | 389 | 77.1 | 70.0 | 28,721 |
| blood pressure decreasedSignal | 376 | 28.6 | 26.0 | 9,967 |
| oxygen saturation decreasedSignal | 248 | 22.3 | 19.7 | 5,012 |
| urticariaSignal | 545 | 16.4 | 15.2 | 7,910 |
| loss of consciousnessSignal | 255 | 10.0 | 8.9 | 2,072 |
| erythemaSignal | 394 | 9.7 | 8.8 | 3,073 |
| chest discomfortSignal | 180 | 8.9 | 7.7 | 1,250 |
| pruritusSignal | 481 | 6.3 | 5.8 | 2,177 |
| dyspnoeaSignal | 621 | 5.5 | 5.1 | 2,356 |
| hypotensionSignal | 193 | 4.8 | 4.2 | 590 |
| vomitingSignal | 293 | 3.1 | 2.8 | 433 |
| rashSignal | 228 | 2.6 | 2.3 | 234 |
| dizzinessSignal | 230 | 2.3 | 2.0 | 175 |
| nauseaSignal | 320 | 2.0 | 1.8 | 174 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.